Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
CARM
CARM | US
0.02
USD0.02
18.90K%
CARM | US
Loading StockChartView...
About CARM
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
08/06/2026
Close
0.02
Open
0.00
High
0.02
Low
0.00
Carisma Therapeutics Inc. a biopharmaceutical company develops chimeric antigen receptors (CAR) macrophages for the treatment of solid tumors. Its solutions are used to play a crucial role in the innate and adaptive immune response and technology leverages advances in macrophage biology chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human diseases. Carisma Therapeutics Inc. has a strategic collaboration agreement with Moderna Inc. Carisma Therapeutics Inc. was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics Inc. in May 2017. The company was incorporated in 2016 and is based in Philadelphia Pennsylvania.
View LessCARM | US
Risk
75028.5
Sharpe
-0.00
Luna's Score
49/100
Recommendation
Hold
Luna says (CARM | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Debt to Equity (> 0.75)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
Loading RiskMeterView...
10 days
122486.0%1 month
75028.5%3 months
44242.4%6 months
29006.9%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
112.50
Debt to equity
10.44
Debt to assets
0.06
Ent. to EBITDA
-0.06
Ent. to rev.
0.40
PEG
-
Other Fundamentals
EBITDA
-72.61M
MarketCap
789.35K
MarketCap(USD)
789.35K
Div. yield
-
Op. margin
-126.89
Erngs. growth
-
Rev. growth
158.30
Ret. on equity
-216.21
Short ratio
7.53
Short perc.
3.32
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.03
Range1M
0.03
Range3M
0.04
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
5.02
Price X volume
2.45K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.06 | 0.53 | Cheaper |
| Ent. to Revenue | 0.40 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 112.50 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 44,242.40 | 72.80 | Riskier |
| Debt to Equity | 10.44 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 789.35K | 3.66B | Emerging |
